FDA expects to have conversations with individual sponsors as it decides whether an approved biologic qualifies for reference product exclusivity under the Biologics Price Competition and Innovation Act.
Speaking at a DIA biosimilars meeting in Washington, D.C. Sept. 19, FDA Office of New Drugs Associate Director for Therapeutic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?